Plan Your Winter Vacay to Do Good in the World

A Weekend Getaway with a Purpose

Sign Up Now for The Leukemia & Lymphoma Society's Team In Training

The days are getting longer and hotter but it's not too soon to make this winter's vacation a life saver. For the experience of a lifetime you can spend the next four to five months preparing for a full or half marathon or century ride at a fabulous destination all while raising money to help fund blood cancer research.

The Leukemia & Lymphoma Society's (LLS) Team In Training® program (TNT) is signing up runners, walkers and cyclists for events at winter destinations including magical Walt Disney World in Orlando, Fla., quaint scenic St. Petersburg, Fla., exotic Honolulu, HI and enchanting San Antonio, TX. Consider combining a fun vacation at a warm winter spot with the opportunity to accomplish an incredible feat and support lifesaving research.

TNT, the world's first, biggest and best sports training and fundraising program, provides participants with a four-to-five month comprehensive training program, certified coaches and travel and accommodations at the venue of their choice. In return, participants help in the fight against leukemia, lymphoma and myeloma by raising funds to support blood cancer research, education and services for patients and their families.

"Taking vacations that include a component for helping others in need is a growing trend," said Donna Grogan, Vice President, Sports Training Programs for LLS. "TNT provides participants a great opportunity to travel to a great destination while also giving them the satisfaction of knowing they are making a difference in the lives of blood cancer patients."

To sign up visit www.teamintraining.org

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap